linjc16/ctgov huggingface dataset:
Effect of Aerobic Training on Asthmatic Patients

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that aerobic training can reduce anxiety, depression and airway inflammation and those benefits may be related to changes in autonomic system.

Detailed Description
-----------------
One-hundred patients with moderate or severe persistent asthma, age ranging from 20 to 50 years-old recruited after a medical consultation. Asthma diagnosis based on GINA1 and patients were under medical treatment for at least 6-months and considered clinically stable (no crises and changes in medication for at least 30 days). Patients diagnosed with cardiovascular, pulmonary or musculoskeletal diseases impairing exercise training were excluded. Experimental Design: Patients were studied between 2 medical consultation to avoid changes in medication during the study and patients were randomized (by drawing lots) into either Control or Training groups. CG was submitted to a 4-hour educational program and a breathing exercise program and TG was submitted to the same CG procedures plus an aerobic training program individually based on VO2max. Before and after the intervention, patients performed pulmonary function test and cardiopulmonary exercise testing and as well as fulfilled questionnaires to quantify asthma specific HRQL and anxiety and depression levels. Asthma daily symptoms were evaluated monthly.

Official Title
-----------------
Effect of Aerobic Training on Psychosocial Morbidity, Symptoms, Airway Inflammation and Autonomic Modulation in Asthmatic Patients

Conditions
-----------------
Anxiety, Depression, Airway Inflammation

Intervention / Treatment
-----------------
* Other: Aerobic training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20-50 years old moderate and severe asthma Exclusion Criteria: other pulmonary or cardiovascular disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patient cousenling<br>Improve medicine use Self control asthma crisis Ambient hygiene | Other: Aerobic training<br>* Treadmill training<br>* Other names: Exercise conditioning;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| psychosocial morbidity and airway inflammation |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| autonomic modulation, aerobic capacity, pulmonary function |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aerobic Exercise, Exercise
Six Months DHEA Treatment in Female Adrenal Failure

Study Overview
=================
Brief Summary
-----------------
DHEA is an adrenal deriven androgen precourser. The impact of DHEA substitution therapy in adrenal failure is unknown as well as the physiologically effects of DHEA is unknown. Effects of physiologically DHEA substitution is investigated in the model of female adrenal failure.

Official Title
-----------------
Physiolocal Effects of 6 Months DHEA Substitutional Therapy in Female Adrenal Failure in a Randomised, Placebo Controlled and Overcrossed Study.

Conditions
-----------------
Adrenal Insufficiency

Intervention / Treatment
-----------------
* Drug: dehydroepiandrosterone (DHEA)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female, Adrenal insuficiency, Stable and safe anticonception, Stable hydrocortison substituation treatment. Exclusion Criteria: Neoplastic and thromboembolic disease, Diabetes mellitus.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: dehydroepiandrosterone (DHEA)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life parameteres, cardiovascular parameters, bodycomposition, exercise parameters, hormonal and serological parameters, fuel metabolisme. |  | six months |
Biomarkers of Homeopathy in Fibromyalgia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy of individualized classical homeopathy in treatment of persons with fibromyalgia and to determine the usefulness of electroencephalographic and electrocardiographic measures to serve as markers of differences between active and placebo treatment.

Conditions
-----------------
Fibromyalgia

Intervention / Treatment
-----------------
* Drug: Active liquid remedy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: ACR diagnosis of fibromyalgia; Willing to take daily active or placebo liquid remedy under double blind conditions for 6 months, involving daily succussion and dilution of source liquid from a stock bottle; Willingness/ability to comply with dietary and lifestyle restrictions, i.e., no coffee in any form, no comphor or menthol-containing products; no electric blankets, no strong aromatics, no routine vaccinations, no concomitant use of acupuncture, chiropractic, polarity therapy, psychic healing, or magnet therapy; No dental drilling, MRI scans unless emergent; Withhold food or drink 30 mins before/after therapy; Stable conventional care for 2 months prior to entry; Willing to undergo 3 diagnostic physical exams, and to permit videotaping of interview sessions; Willing to fill out questionnaires Exclusion criteria: Steroid-dependent medical conditions; Chronic benzodiazepine or anticonvulsant use; Use of tricyclic antidepressants, antihypertensives, and other drugs that alter orthostasis; Pregnancy; History of seizure disorder or syncope; Life-threatening medical conditions; Current active asthma; History of anaphylactic shock; Insulin-dependent diabetes; Active suicidal ideation or psychosis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Active liquid remedy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EKG, EEG, fibromyalgia, homeopathy, chronic pain
International PRospective Multicenter Study On RadiaTion Dose Estimates Of Coronary CT AngIOgraphy IN Daily Practice

Study Overview
=================
Brief Summary
-----------------
Estimation of radiation dose of coronary multislice computed tomography (MSCT) angiography in daily practice in an international, multicenter and vendor-independent trial.

Detailed Description
-----------------
Prospective analysis of cardiac CT angiographies enrolled over 1 month Collection of 1 axial data set and the patient dose protocol (including kV, mAs, CTDI, DLP, etc.) on a CD Dose estimation in dose/cm with the use of a method proposed by the European Working Group for Guidelines on Quality Criteria in CT. Assessment of diagnostic, qualitative image quality on a per-vessel basis by the participating study sites and in randomly selected cases by the primary study investigators (approximately 5-10% of patients to spot check interobserver variability of image quality assessments) Assessment of image quality with the use of quantitative parameters including image noise, signal-to-noise and contrast-to-noise ratios

Official Title
-----------------
International PRospective Multicenter Study On RadiaTion Dose Estimates Of Coronary CT AngIOgraphy IN Daily Practice

Conditions
-----------------
Coronary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: assessment of coronary arteries acute chest pain or triple rule out evaluation after PCI (stents) evaluation of bypass grafts before or after EP study cardiac anomalies Exclusion Criteria: pregnancy contraindications against contrast media

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radiation dose estimates of coronary MSCT angiography in daily practice |  | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of dose estimates between 16-slice, 64-slice, DSCT and other CT systems |  | 1 month | 
| Frequency of dose-saving algorithm's use (e.g.: ECG-dose pulsing / Care Dose 4D / 100kv |  | 1 month | 
| Assessment of potentials for additional dose savings (e.g. entire scan length; the distance between scan start to begin of coronary arteries and distance end of coronary arteries to end of scan) |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary CT angiography, radiation dose estimates
The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm

Study Overview
=================
Brief Summary
-----------------
The matrix metalloproteinase-9 (MMP-9) is considered to play a central role in abdominal aortic aneurysm (AAA) initiation. Doxycycline has direct MMP-9 inhibiting properties in vitro, and it effectively suppresses AAA development in rodents. Observed inhibition of AAA progression, and contradictory findings in human studies evaluating the effect of doxycycline therapy on aortic wall MMP-9 suggest that the effects of doxycycline extend beyond MMP-9 inhibition, and that the effect may be dose dependent.

Detailed Description
-----------------
In this clinical trial, we evaluated the effect of two weeks of low (50 mg/day), medium (100 mg/day) or high dose (300 mg/day) doxycycline versus no medication in patients undergoing elective AAA repair. The effect of doxycycline treatment on MMP and cysteine proteases, and their respective inhibitors was evaluated in an integrative approach.

Official Title
-----------------
The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm

Conditions
-----------------
Aortic Aneurysm, Abdominal

Intervention / Treatment
-----------------
* Drug: doxycycline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective open aneurysm repair Exclusion Criteria: Severe kidney and liver dysfunction
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: 1<br> | |
| Active Comparator: 2<br>doxycycline 50 mg/day | Drug: doxycycline<br>* 2 weeks once daily<br>|
| Active Comparator: 3<br>doxycycline 100 mg | Drug: doxycycline<br>* 2 weeks once daily<br>|
| Active Comparator: 4<br>doxycycline 300 mg | Drug: doxycycline<br>* 2 weeks once daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collagenase mRNA and protein expression |  | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Collagenases, MMP, Cathepsins, Doxycycline, Aneurysm
To Evaluate the Performance and Safety of Personalized Implants in CMF Surgery Indicated for Orthognathic Surgery

Study Overview
=================
Brief Summary
-----------------
With the digital age, guided surgery and cases of fully computer-assisted surgeries via 3D printing guides and preformed plates are booming. Our project aims to study the performance and safety of personalized implants (personalized guides and plates) in orthognathic surgery in order to obtain specific clinical data on SLS France devices.

Official Title
-----------------
Prospective Study to Evaluate the Performance and Safety of Personalized Implants in Cranio-Maxillofacial (CMF) Surgery Indicated for Orthognathic Surgery

Conditions
-----------------
Surgery, Maxilla Fracture

Intervention / Treatment
-----------------
* Device: Personalized guides and plates


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patient, adult or minor having reached bone maturity according to the judgment of the investigator, Patient having first orthognathic surgery with SLS France personalized guides and plates, Patient who received orthodontic treatment prior to orthognathic surgery, Patient able to read, understand and answer the study quality of life questionnaire, Patient (and legal representative if a minor) who is not opposed to his participation in the study or to the processing of his data. Patient affiliated to a social insurance Exclusion Criteria: Patient allergic to one of the compounds of the plates and / or guides, Patient with physical or mental disability making it impossible to follow up in the study, Patient with significant expansion Patient with a congenital craniofacial malformation Patient with acute or chronic local or systemic infection, Person placed under legal protection, Pregnant or breastfeeding women.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Orthognatic surgery<br>Orthognathic surgery patients, adults or minors whose bone maturity is sufficient according to the investigator. | Device: Personalized guides and plates<br>* Patients will be included in the study and then followed clinically according to the routine care of orthognathic surgery with personalized guides and plates. The only specific act this study is the completion of an OQLQ quality of life questionnaire by patients preoperatively and between 8 to 12 months postoperatively.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Orthognatic quality of life questionnaire | To evaluate the performance of personalized implants indicated for orthognathic surgery by measuring the quality of life of patients | 12 months post-operatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
orthognatic surgery, guided surgery, 3D printing
Effect of Cognitive Aid on Adherence to Perioperative Guidelines

Study Overview
=================
Brief Summary
-----------------
The objective of this prospective randomized trial is to ascertain whether the use of a cognitive aid improves adherence to best published practices for the management of simulated patients regarding perioperative cardiac evaluation and management.

Official Title
-----------------
Effect of Cognitive Aid on Adherence to Perioperative Guidelines

Conditions
-----------------
Perioperative Decision Making

Intervention / Treatment
-----------------
* Other: Cognitive Aid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any active resident or faculty member will be allowed to volunteer. Exclusion Criteria: There are no exclusion criteria (notably we will include residents on academic probation)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Crossover Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Memory<br> | |
| Experimental: Cognitive Aid<br> | Other: Cognitive Aid<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence of ACC/AHA Guideline | Adherence in terms of selection of the correct option for multiple choice question. | Up to 6 weeks |
Corneal Opacities in Children

Study Overview
=================
Brief Summary
-----------------
A prospective observational study on corneal opacities in infants and children (1 month to 18 years old) will be conducted at CHLA. Most of these cases will be due to congenital corneal opacity (e.g. Peter's anomaly, mucopolysacharidoses) or scarring due to infectious keratitis. Sixty (60) subjects will be recruited. The children will be examined under anesthesia with a portable slit-lamp and OCT. An iVue OCT system (Optovue) attached to an operating microscope-style mount at CHLA will be used for the intraoperative scans. Both cross-sectional and 3-D OCT scans will be performed to assess opacity depth, pachymetry map, endothelial defects, and any abnormal adhesion between the cornea, iris and lens. The anterior chamber angle will also be imaged with cross-sectional OCT to assess angle depth, trabecular meshwork, Schwalbe's line, and possible peripheral iridocorneal adhesion or posterior embryotoxon. OCT of the crystalline lens will be obtained to assess the presence of cataract. Slit-lamp photography will be obtained, and gonioscopy will be performed if indicated. Corneal diameter will be measured with a caliper, and intraocular pressure will be measured with a tonopen (Reichert).

Official Title
-----------------
Observational Study on Corneal Opacities in Children

Conditions
-----------------
Corneal Opacities

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants and children (1 month to 18 years of age) with corneal opacity requiring a thorough eye examination. Exclusion Criteria: Inability to give informed consent. Inability to maintain stable fixation for OCT imaging. Inability to commit to required visits to complete the study.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of suitable subjects | The primary goal of the study will be to identify subjects suitable for the trial with OCT-guided LALAK. The determination will be based on analysis of clinical history & OCT corneal images as well as the subjects' willingness to participate in the study. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
corneal opacities, Optical coherence tomography
Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell Lymphoma

Study Overview
=================
Brief Summary
-----------------
Although modern radiation techniques combined with chemotherapy has greatly improved the local control and long-term survivals for patients with early-stage NKTCL, relapse and systemic dissemination are common for localized patients. Relapsed/refractory diseases together with advanced stage NKTCLs uaually progress rapidly with poor prognosis (5-year overall survival rate, 0-20%). According to published studies, some recurrent genetic alternations have been identified in NKTCL, including oncogene/tumor suppressive gene abberants, epigenetic changes, cellular signaling pathways abnormalities, cellular apoptosis related genes and so forth. However, the gene profiling techniques and materials vary in different studies, no consensus has been reached on the gene abnormalities of advanced, or relapsed/refractory NKTCL up to now. Additionally, gene sequencing using ctDNA of peripheral blood has been unexploited in NKTCL patients.

Official Title
-----------------
Target Gene Sequencing for Advanced Stage, Relapsed/Refractory Natural Killer/T-cell Lymphoma and the Correlation Between Gene Abmormalities and Chemotherapy Efficacy

Conditions
-----------------
Lymphoid Neoplasm

Intervention / Treatment
-----------------
* Other: non-interventional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of NKTCL with typical morphology and immunophenotype, according to the 2008 World Health Organization classification of lymphomas; stage III/IV disease; or relapsed or refractory disease after at least one line prior teratment; age ≥ 18 years; ECOG performance status 0-2; at least one measurable lesion; adequate hematological, hepatic, and renal functions; life expectancy of more than 3 months. Exclusion Criteria: Previously untreated stage I/II disease; with no adequate tumour tissue; any coexisting medical problems of sufficient severity to prevent full compliance with the study protocol.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: non-interventional|non-interventional|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concordance | The concordance of plasma cfDNA genotyping and tumor genotyping is defined as the ratio of gene variants detected in tumor and cfDNA to variants identified in tumor | 2 years |